Literature DB >> 8757021

Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease.

R L Albin1, S Minoshima, C J D'Amato, K A Frey, D A Kuhl, A A Sima.   

Abstract

We report six demented individuals with pathologically verified diffuse Lewy body disease (DLBD) studied with fluoro-deoxyglucose positron emission tomography (FDG-PET). Three subjects had pure DLBD and three subjects had combined DLBD and Alzheimer's disease (DLBD-AD) pathology. FDG-PET revealed evidence of diffuse cerebral hypometabolism in both pure DLBD and DLBD-AD with marked declines in association cortices with relative sparing of subcortical structures and primary somatomotor cortex, a pattern reported previously in AD. Unlike AD, however, these subjects also had hypometabolism in the occipital association cortex and primary visual cortex. These findings indicate the presence of diffuse cortical abnormalities in DLBD and suggest that FDG-PET may be useful in discriminating DLBD from AD antemortem.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757021     DOI: 10.1212/wnl.47.2.462

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  46 in total

1.  Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction?

Authors:  Tamara G Fong; Sharon K Inouye; Weiying Dai; Daniel Z Press; David C Alsop
Journal:  Brain Imaging Behav       Date:  2011-03       Impact factor: 3.978

Review 2.  Applications of positron emission tomography (PET) in neurology.

Authors:  Y F Tai; P Piccini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

Review 3.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

4.  Visual search in Dementia with Lewy Bodies and Alzheimer's disease.

Authors:  Kelly M Landy; David P Salmon; J Vincent Filoteo; William C Heindel; Douglas Galasko; Joanne M Hamilton
Journal:  Cortex       Date:  2015-09-21       Impact factor: 4.027

Review 5.  Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.

Authors:  Peter J Nestor; Daniele Altomare; Cristina Festari; Alexander Drzezga; Jasmine Rivolta; Zuzana Walker; Femke Bouwman; Stefania Orini; Ian Law; Federica Agosta; Javier Arbizu; Marina Boccardi; Flavio Nobili; Giovanni Battista Frisoni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-07       Impact factor: 9.236

6.  Motion discrimination in dementia with Lewy bodies and Alzheimer disease.

Authors:  Kelly M Landy; David P Salmon; Douglas Galasko; J Vincent Filoteo; Elena K Festa; William C Heindel; Lawrence A Hansen; Joanne M Hamilton
Journal:  Neurology       Date:  2015-09-23       Impact factor: 9.910

7.  Hippocampal hypometabolism predicts cognitive decline from normal aging.

Authors:  Lisa Mosconi; Susan De Santi; Juan Li; Wai Hon Tsui; Yi Li; Madhu Boppana; Eugene Laska; Henry Rusinek; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-01-11       Impact factor: 4.673

8.  Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease.

Authors:  Haruo Hanyu; Soichiro Shimizu; Kentaro Hirao; Hidekazu Kanetaka; Toshihiko Iwamoto; Taishiro Chikamori; Yasuhiro Usui; Akira Yamashina; Kiyoshi Koizumi; Kimihiko Abe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-11-22       Impact factor: 9.236

Review 9.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

10.  Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies.

Authors:  Joanne M Hamilton; David P Salmon; Douglas Galasko; Rema Raman; Jenn Emond; Lawrence A Hansen; Eliezer Masliah; Leon J Thal
Journal:  Neuropsychology       Date:  2008-11       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.